Navigation Links
ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
Date:4/8/2009

FREDERICK, Md., April 8 /PRNewswire/ -- ImQuest Life Sciences presented their latest biological results supporting the continued development of their novel small molecule piperazine compound for the treatment of solid tumors at the Targeted Cancer Therapeutics meeting held in Whistler, British Columbia. The presentation highlighted advances in the development of ImQuest's lead microtubule inhibitor, IQP-0304. The piperazines demonstrate potent antiproliferative activity against a variety of tumor cell types (prostate, lung, ovary, colon, CNS, melanoma, and hematopoietic lineages) by disruption of cell cycle progression and induction of apoptosis with a secondary anti-angiogenic activity as a consequence of the cytoskeletal disruption. The unique activity, novel structure, potent in vivo efficacy in murine xenograft models, as well as a favorable toxicity profile, potential for oral bioavailability and straight-forward cGMP manufacturing suggest that IQP-0304 might be an important addition to the currently available therapeutic regimens used to treat solid tissue malignancies. Dr. Nick Kaludov, Ph.D., Director of Scientific Operations, presented the new findings which also included toxicology and toxicokinetic evaluations.

"These results highlight the significant potential of the piperazines as highly potent and broadly active chemotherapeutic agents and provide additional rationale for their expedited development," said Dr. Robert W. Buckheit Executive Vice President and Chief Scientific Officer, and presentation co-author.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.

    For further information regarding this press release please contact:
    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.
    301-696-0274
    rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C.
2. ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs
3. ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
4. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
5. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
6. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference
8. Encision Enters Into Sales Representation Agreement With Caldera Medical
9. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
10. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
11. Alexzas Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... of medical marijuana products targeting the needs of consumers who are incorporating medical ... takes place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, ...
Breaking Biology Technology:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
Breaking Biology News(10 mins):